LakeShore Biopharma Co., Ltd (LSB)
After hours:
LakeShore Biopharma Co., Ltd
Building No. 2
38 Yongda Road Daxing Biomedical Industry Park Daxing District
Beijing 102629
China
86 10 8920 2086
https://www.ysbiopharm.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 758
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Gang Li | Head of Marketing & Sales | N/A | N/A | 1982 |
| Dr. Yuan Liu Ph.D. | Head of Vaccine Research | N/A | N/A | 1987 |
| Mr. Wang Xu | CEO & Director | N/A | N/A | 1971 |
| Dr. Hui Shao C.F.A., M.B.A., Ph.D. | President, Chief Business Officer & Vice Chairman | N/A | N/A | 1968 |
| Ms. Rui Yu M.B.A., M.S. | CFO & Director | N/A | N/A | 1975 |
| Dr. Zenaida Reynoso Mojares M.D. | Chief Medical Officer | N/A | N/A | 1959 |
Description
LakeShore Biopharma Co., Ltd, a biopharmaceutical company, engages in the discovering, developing, manufacturing, commercializing, and sale of vaccines and therapeutic biologics for infectious diseases and cancer. The company's product pipeline includes YSJA, a conventional rabies vaccine which is in marketed stage; PIKA, a rabies vaccine which are in phase I/III and preclinical trials for the treatment of rabies virus; PIKA YS-ON-001, an immuno-oncology therapeutic that is in phase I trials for the treatment of pancreatic and hepatocellular cancer; PIKA YS-HBV-001, a hepatitis B vaccine that is in phase I trials; PIKA YS-HBV-002, an immune-therapy vaccine which is in IND preclinical trials for the treatment of chronic HBV infection; and PIKA YS-ON-001 and PIKA Influenza Vaccine which are in preclinical trials. It operates in China, Singapore, the United States, and the Philippines. The company was formerly known as YS Biopharma Co., Ltd. and changed its name to LakeShore Biopharma Co., Ltd in May 2024. The company was founded in 2002 and is based in Beijing, China.
Corporate Governance
LakeShore Biopharma Co., Ltd’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
